Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish
- 997 Downloads
Safety concerns have been raised regarding the association of chronic consumption of artificial sweeteners (ASs) with metabolic disorders, especially in the heart and brain. There has been no information on the in vivo physiological effects of AS consumption in lipoprotein metabolism. High-dosage treatment (final 25, 50, and 100 mM) with AS (aspartame, acesulfame K, and saccharin) to human high-density lipoprotein (HDL) induced loss of antioxidant ability along with elevated atherogenic effects. Aspartame-treated HDL3 (final 100 mM) almost all disappeared due to putative proteolytic degradation. Aspartame- and saccharin-treated HDL3 showed more enhanced cholesteryl ester transfer activity, while their antioxidant ability was disappeared. Microinjection of the modified HDL3 exacerbated the inflammatory death in zebrafish embryos in the presence of oxLDL. These results show that AS treatment impaired the beneficial functions of HDL, resulting in loss of antioxidant and anti-atherogenic activities. These results suggest that aspartame and saccharin could be toxic to the human circulation system as well as embryonic development via impairment of lipoprotein function.
KeywordsArtificial sweetener High-density lipoprotein Atherosclerosis Zebrafish
This work was supported by the 2014 Yeungnam University Research Grant.
- 3.Jang, W., Jeoung, N. H., & Cho, K. H. (2011). Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state. Molecules and Cells, 31, 461–470.CrossRefPubMedCentralPubMedGoogle Scholar
- 7.Park, K. H., Jang, W., Kim, K. Y., Kim, J. R., & Cho, K. H. (2010). Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochemical and Biophysical Research Communications, 392, 295–300.CrossRefPubMedGoogle Scholar
- 8.Roberts, H. J. (2003). Aspartame disease: An ignored epidemic. Ontario: Sunshine Sentinel Press.Google Scholar
- 17.Park, K. H., Shin, D. G., Kim, J. R., & Cho, K. H. (2010). Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 65, 600–610.CrossRefGoogle Scholar
- 18.Park, K. H., & Cho, K. H. (2011). High-density lipoprotein (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share proatherosclerotic and prosenescent properties with increased cholesterol influx. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 66, 511–520.CrossRefGoogle Scholar
- 20.Nusslein-Volhard, C., & Dahm, R. (2002). Zebrafish: A practical approach. New York: Oxford University Press.Google Scholar
- 26.Johnson, R. J., Segal, M. S., Sautin, Y., Nakagawa, T., Feig, D. I., Kang, D. H., et al. (2007). Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. American Journal of Clinical Nutrition, 86, 899–906.PubMedGoogle Scholar
- 29.Soffritti, M., Belpoggi, F., Esposti, D. D., & Lambertini, L. (2005). Aspartame induces lymphomas and leukaemias in rats. European Journal of Oncology, 10, 107–116.Google Scholar
- 31.Eshak, E. S., Iso, H., Kokubo, Y., Saito, I., Yamagishi, K., Inoue, M., et al. (2012). Soft drink intake in relation to incident ischemic heart disease, stroke, and stroke subtypes in Japanese men and women: The Japan Public Health Centre-based study cohort I. American Journal of Clinical Nutrition, 96, 1390–1397.CrossRefPubMedGoogle Scholar